ClinicalTrials.gg
RecruitingNCT07271147Updated Sep 29, 2026

Effects of taVNS Combined With Dexmedetomidine on POVN

An interventional study of Transcutaneous Auricular Vagus Nerve Stimulator and Dexmedetomidine in Postoperative Nausea and Vomiting, sponsored by Affiliated Hospital of Nantong University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Affiliated Hospital of Nantong University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Sep 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Postoperative Nausea and Vomiting with a site in China — 14 open to participants now, 15 under way, none of them phase 3. Postoperative Nausea and Vomiting · China.

Planned enrollment
28th of 44
176 · median 200
Started
2025
with 5 others
No phase
31 of 56
11 open now
Primary completion
2026-12
later than 9 of 14 live
Registered
49th of 56
by date
Lead sponsor
1 of 56
Affiliated Hospital of Nantong University

Among the 56 studies in Postoperative Nausea and Vomiting with a site in China, this one is the 28th largest by planned enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2025, is one of 31 with no phase, reaches primary completion later than 9 of the 14 other live ones, and was the 49th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

14 of the 56 studies in Postoperative Nausea and Vomiting with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Postoperative Nausea and Vomiting with a site in China, or all of them as a file.
02

Study summary

To explore the effects and possible mechanisms of dexmedetomidine combined with taVNS on the incidence of postoperative nausea and vomiting in female patients undergoing laparoscopic surgery

Read the detailed description

Patients are recruited one week prior to the start of the trial, during which they are informed about the experimental protocol and associated risks. After obtaining informed consent and signatures, they are enrolled as study participants. Patients who meet the trial criteria are randomly assigned in a 1:1 ratio to the control group (sham taVNS group) and the intervention group (taVNS group, with taVNS intervention starting 30 minutes prior to anesthesia induction and continuing until the end of surgery, terminating after the removal of the endotracheal tube in the PACU), in a double-blind manner (with taVNS intervention and postoperative follow-up conducted by different researchers).

03

Conditions studied

  • Postoperative Nausea and Vomiting
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 65;
  • Elective laparoscopic surgery under general anesthesia;
  • Classified as (ASA) physical status I to II;
  • Capable of understanding the study procedures and various assessment scales and able to effectively communicate with the researchers;
  • Willing to participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Patients with ASA anesthesia classification ≥ III;
  • Poorly controlled hypertension, atrioventricular block ≥ second degree, obesity ( > 30 kg/m²);
  • Pregnant or breastfeeding;
  • Known allergy to drugs used in the study protocol, history of traumatic brain injury, history of gastrointestinal surgery;
  • Liver or kidney dysfunction (liver enzymes or creatinine ≥ 1.5 times the normal value), alcoholism or drug abuse, mental illness, use of antiemetics, opioids, psychoactive drugs, or within 24 hours before surgery;
  • Patients with implanted stimulators (such as pacemakers, implantable vagus nerve stimulators, deep brain stimulators, spinal cord stimulators, etc.), cochlear implants, or metal implants (except in dental cases);
  • Skin lesions or dermatological diseases at the site of electrical stimulation;
  • Preoperative heart rate \< 50 bpm or the presence of sinoatrial node disease or second-degree or higher atrioventricular block;
  • Patients unable to cooperate with assessments;
  • Patients participating in other clinical trials.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine combined with taVNS(taVNS group)

    Patients in the taVNS group will have a transcutaneous auricular vagus nerve stimulation device with a transparent, non-insulated thin film placed on the cymba conchae of the left ear. TaVNS will be administered on the day of surgery (starting 30 minutes before anesthesia induction and continuing until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU). The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold). Dexmedetomidine was administered intravenously by infusion pump (0.5 μg/kg over 10 minutes, followed by continuous infusion at 0.4 μg/kg/h) in combination with taVNS (initiated 30 minutes before anesthesia induction and terminated after tracheal tube removal in the PACU upon the conclusion of the surgery).

    Device: Transcutaneous Auricular Vagus Nerve Stimulator · Drug: Dexmedetomidine

  • Sham comparator
    Dexmedetomidine combined with sham transcutaneous auricular vagus nerve stimulation

    Patients in the Sham taVNS group will have a transcutaneous auricular vagus nerve stimulation device with a transparent insulating film placed on the cymba conchae of the left ear on the day of surgery. The stimulation parameters, method, and duration will be the same as those in the taVNS group. However, due to the insulating film applied to the stimulation device in the sham group, patients will not actually receive any stimulation. Dexmedetomidine was administered intravenously by infusion pump (0.5 μg/kg over 10 minutes, followed by continuous infusion at 0.4 μg/kg/h) in combination with taVNS (initiated 30 minutes before anesthesia induction and terminated after tracheal tube removal in the PACU upon the conclusion of the surgery).

    Drug: Dexmedetomidine

Interventions

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulator

    Intervention Timing of Transcutaneous Auricular Vagus Nerve Stimulator: The intervention will begin 30 minutes before anesthesia induction and continue until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU. The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold).

  • Dexmedetomidine was administered intravenously by infusion pump (0.5 μg/kg over 10 minutes, followed by continuous infusion at 0.4 μg/kg/h) in combination with taVNS (initiated 30 minutes before anesthesia induction and terminated after tracheal tube removal in the PACU upon the conclusion of the surgery).

06

What researchers measure

Primary outcomes

  1. Incidence of Postoperative PONV

    Patients who experience at least one episode of nausea, vomiting, or retching, or any combination of these, within the first 24 hours after surgery are considered to have PONV.

    Time frame: The first 24 hours postoperatively

Secondary outcomes

  1. The frequency of nausea, retching and vomiting within 2 hours, 6 hours, 24 hours and 48 hours after surgery.

    Postoperative nausea is defined as the occurrence of nausea at least once without retching or vomiting. Retching is defined as the patient experiencing regular spasms in the chest and abdominal muscles without the expulsion of gastric contents. Vomiting is defined as vomiting or retching at least once.

    Time frame: From 2 hours postoperatively to 48 hours postoperatively

  2. Frequency of remedial antiemetic administration within 2 hours, 6 hours, 24 hours and 48 hours after surgery.

    Time frame: From 2 hours postoperatively to 48 hours postoperatively

  3. The severity of nausea and vomiting within 2 hours, 6 hours, 24 hours and 48 hours after surgery.

    Severity was assessed using a 4-point Likert scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

    Time frame: From 2 hours postoperatively to 48 hours postoperatively

  4. Incidence of PONV at 2 hours, 6 hours, and 48 hours postoperatively

    Patients who experienced at least one episode of nausea, vomiting, retching, or any combination thereof within the first 2, 6, or 48 hours after surgery were considered to have PONV.

    Time frame: From 2 hours postoperatively to 48 hours postoperatively

  5. Postoperative NRS pain scores at 2 h, 6 h, 24 h, and 48 h

    The NRS (Numerical Rating Scale) is used to assess the intensity of pain.Minimum: 0 Maximum: 10.The higher the score, the more severe the pain.

    Time frame: From 2 hours postoperatively to 48 hours postoperatively

  6. Number of patient-controlled analgesia (PCA) pump activations at 2 h, 6 h, 24 h, and 48 h after surgery

    Time frame: From 2 hours postoperatively to 48 hours postoperatively

  7. Frequency of rescue analgesic use at 2 h, 6 h, 24 h, and 48 h postoperatively

    Time frame: From 2 hours postoperatively to 48 hours postoperatively

  8. Intraoperative incidence of hypotension and bradycardia

    Hypotension was defined as a mean arterial pressure \< 60 mmHg, and bradycardia as a heart rate \< 50 bpm.

    Time frame: during surgery

  9. Incidence of other adverse reactions within 48 h after surgery (dizziness, somnolence, dry mouth, skin irritation).

    Time frame: The first 48 hours postoperatively

  10. Preoperative and 24-hour postoperative Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) is used to assess the severity of anxiety and depression in individuals. Full scale title: Hospital Anxiety and Depression Scale (HADS) - Full 14-Item Version Minimum score: 0 Maximum score: 42 (0-21 for the anxiety subscale and 0-21 for the depression subscale) Interpretation: Higher scores indicate greater severity of anxiety and/or depression, representing worse outcomes.

    Time frame: From 1 day preoperatively to 24 hours postoperatively

  11. PROMIS SD-SF 8a Assessment on Preoperative and 24-hour Postoperative

    The Patient-Reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8a (PROMIS SD-SF 8a) is an 8-item self-reported questionnaire developed by the Patient-Reported Outcomes Measurement Information System to assess sleep disturbance over the past 7 days. It evaluates aspects such as difficulty falling asleep, sleep maintenance, sleep quality, and daytime functioning, providing a standardized measure of sleep disturbance severity. Full scale title Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8a (PROMIS SD-SF 8a) - 8-Item Version Score range Minimum: 8 Maximum: 40 Interpretation Higher scores indicate greater sleep disturbance over the past seven days, corresponding to worse outcomes.

    Time frame: From 1 day preoperatively to 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 181 non-industry interventional studies with no phase under Postoperative Nausea and Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 11 months is below that.

Counting every sponsor, half of 181 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

Start moved once since we started tracking on Sep 25, 2026: Nov 2025 → Dec 2025, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 9, 2025
StartActual
Dec 7, 2025was Nov 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 7, 2025→Dec 7, 2025
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Nov 7, 2025→Dec 7, 2025
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07271147
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Chaochao Zhong (Principal Investigator, Affiliated Hospital of Nantong University) — Principal investigator
First posted
Dec 9, 2025
Start date
Dec 7, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

Chao-Chao Zhong, M.D.;P.h.D
Contact
zhong249767626@163.com
15152460489
Chao-Chao Zhong
principal investigator · Affiliated Hospital of Nantong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion